Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 05/14/2013

Company Name Symbol %Change
INTEROIL COR IOC
9.57%
INFORMATION III
9.47%
AMR CORP AAMRQ
6.83%
SCIENTIFIC L SCIL
5.26%
PACER INTL I PACR
5.23%
Bottom 5 Companies in the Pharmaceuticals Industry with the Lowest Relative Performance (AKRX, IPXL, QCOR, PRGO, VVUS)

Print Share

May 10, 2013 (Fast Lane via COMTEX) -- Below are five companies in the Pharmaceuticals industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.

Akorn (NASDAQ:AKRX) ranks first with a loss of 7.46%; Impax Laboratories (NASDAQ:IPXL) ranks second with a loss of 3.48%; and Questcor Pharmaceuticals (NASDAQ:QCOR) ranks third with a loss of 2.59%.

Perrigo (NASDAQ:PRGO) follows with a loss of 2.15% and Vivus (NASDAQ:VVUS) rounds out the bottom five with a loss of 1.63%.Akorn, Inc. develops, manufactures, and markets ophthalmic and injectable pharmaceutical products. The Company sells various diagnostic and therapeutic pharmaceutical products focused primarily on ophthalmology, anesthesia, antidotes, and rheumatology. Akorn also markets ophthalmic surgical instruments and other supplies, and provides contract manufacturing for third parties.

---------------------------------------------------------------------------------------------

Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.

Copyright, Comtex News Network, Inc. 2013

Free Stock Analysis From Zacks

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.